BR100 Increased By (0.04%)
BR30 Decreased By (-0.04%)
KSE100 Increased By (0.02%)
KSE30 Increased By (0.02%)
AGHA 6.62 Decreased By ▼ -0.05 (-0.75%)
BECO 4.38 Increased By ▲ 0.03 (0.69%)
BML 56.17 Decreased By ▼ -1.15 (-2.01%)
BOP 30.09 Decreased By ▼ -0.03 (-0.1%)
CNERGY 12.98 No Change ▼ 0.00 (0%)
CSIL 5.32 Increased By ▲ 0.01 (0.19%)
FCCL 51.70 Increased By ▲ 0.05 (0.1%)
FFL 14.48 Decreased By ▼ -0.01 (-0.07%)
FNEL 1.24 Increased By ▲ 0.03 (2.48%)
KEL 6.04 Decreased By ▼ -0.02 (-0.33%)
KOSM 5.87 Increased By ▲ 0.03 (0.51%)
LOTCHEM 26.15 Decreased By ▼ -0.02 (-0.08%)
MLCF 91.15 Decreased By ▼ -0.08 (-0.09%)
NBP 163.95 Decreased By ▼ -0.24 (-0.15%)
NCPL 53.20 Increased By ▲ 0.02 (0.04%)
NPL 59.30 Increased By ▲ 0.18 (0.3%)
OGDC 313.00 Decreased By ▼ -0.39 (-0.12%)
PACE 9.85 Increased By ▲ 0.08 (0.82%)
PAEL 35.20 Decreased By ▼ -0.04 (-0.11%)
PIBTL 14.74 Increased By ▲ 0.03 (0.2%)
PPL 220.40 Decreased By ▼ -0.96 (-0.43%)
PRL 91.91 Increased By ▲ 0.69 (0.76%)
PTC 59.32 Increased By ▲ 0.13 (0.22%)
SSGC 23.37 Increased By ▲ 0.07 (0.3%)
TBL 8.83 Increased By ▲ 0.08 (0.91%)
TELE 7.65 Increased By ▲ 0.04 (0.53%)
TPL 22.03 Decreased By ▼ -0.32 (-1.43%)
TPLP 12.70 Increased By ▲ 0.14 (1.11%)
TREET 21.75 Increased By ▲ 0.02 (0.09%)
TRG 55.62 Decreased By ▼ -0.17 (-0.3%)
Business & Finance

Russia's Sputnik V developers to sue Brazilian regulator for 'false information' about their vaccine

  • The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.
  • A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.
Published Updated
By

MOSCOW: Russian developers of the Sputnik V vaccine against COVID-19 said on Thursday that they were suing Brazilian regulator Anvisa for defamation, accusing it of having knowingly spread false information without testing their product.

The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.

A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.

Sputnik V's official Twitter account on Thursday cited a Brazilian media story citing the same expert as saying that no tests had been carried out to test the Brazilian theory.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," it said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Comments

Comments are closed for this article.